Business ❯Mergers and Acquisitions ❯Corporate Finance
Public Companies Shareholder Value
The acquisition solidifies BMS's control over Abecma, a CAR T-cell therapy for multiple myeloma, as 2seventy Bio concludes its turbulent independent run.
